Financial Data and Key Metrics Changes - The company reported full year revenue from continuing operations of $176.2 million, exceeding the high end of prior guidance, reflecting strong momentum across core markets [13] - The gross margin improved to 47%, with a $12 million year-over-year improvement in adjusted EBITDA [19] Business Line Data and Key Metrics Changes - Revenue from commercial cell and gene therapy increased by 29% year-over-year to a record $33.4 million, representing 20% of overall revenue in Q4 [14][15] - Clinical trial revenue grew 14% year-over-year to $47.1 million, supporting a record 760 clinical trials and 20 commercial therapies worldwide [15][121] - Revenue from life sciences services segment increased by 18% year-over-year, including a 22% growth in biostorage and bioservices revenue [18][121] - The life sciences product segment saw a 7% year-over-year revenue growth [20] Market Data and Key Metrics Changes - The company supports approximately 70% of total clinical trials in the cell and gene therapy industry, with a significant pipeline of 86 clinical trials in phase 3 and 361 in phase 2 [16][121] - The company anticipates 13 BLA or MAA application filings in 2026, with 2 already filed [16] Company Strategy and Development Direction - The company aims to expand services in life sciences by broadening revenue streams and capturing more revenue per client [18] - Strategic partnerships with DHL, Cardinal Health, and Parexel are expected to enhance market position and drive standardization in the cell and gene therapy ecosystem [27][29][88] - The company is leveraging generative AI to enhance internal workflows and operations [25][26] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth trajectory for 2026, with full year revenue guidance set at $190 million to $194 million [30] - The company expects to achieve positive adjusted EBITDA in the second half of 2026 [30] - Management noted that the macro environment remains volatile but sees strong interest in services provided [68] Other Important Information - The financials of CRYOPDP are now presented as discontinued operations following its sale to DHL [9] - The company is investing in global supply chain centers in Paris and California to enhance service capabilities [24] Q&A Session Summary Question: Guidance on growth in biologics and services - Management expects continued progress with existing customers and new commercial therapies, with commercial revenue growing by 29% in 2025 [38][39] Question: Clarification on Q1 expectations - Management reported a solid start to Q1 with no expected disruptions from geopolitical issues [50] Question: Impact of funding environment on customer orders - Funding typically influences customer orders after about a six-month lag [55] Question: Expectations for FDA approvals and growth contributions - Management indicated moderate growth from animal health and reproductive health, with cell and gene therapy being the primary growth driver [72] Question: Update on DHL partnership integration - The integration with DHL is ongoing, and full benefits will take time to materialize [83] Question: Insights on product revenue growth - Management noted that MVE's growth should be assessed on an annual basis rather than quarterly due to the nature of capital equipment purchases [101]